---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-22-012039"
form_type: "8-K"
ticker: "CLSDQ"
cik: "0001539029"
company_name: "Clearside Biomedical, Inc."
filed_at: "2022-06-23T23:59:59+00:00"
generated_at: "2026-06-24T23:38:17.425037+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.3
calibrated_materiality_score: 0.3
confidence: "high"
source: SEC EDGAR
---

# Clearside Biomedical shareholders approve doubling authorized common stock to 200M shares

## Summary
- Shareholders approved amendment to increase authorized common shares from 100M to 200M (32.6M for, 4.4M against, 6.0M abstain).
- Directors George Lasezkay and Christy Shaffer elected with 25.9M and 24.8M votes for, respectively.
- Advisory vote on executive compensation passed with 27.6M for, 3.0M against; annual frequency chosen.
- Ratification of Ernst & Young as auditor for FY2022 received 42.9M votes for, 88.8K against.
- Annual meeting turnout: 43.0M of 60.2M shares represented (71.55% quorum).

## SEC filing metadata
- accession: 0000950170-22-012039
- form_type: 8-K
- ticker: CLSDQ
- cik: 0001539029
- company_name: Clearside Biomedical, Inc.
- filed_at: 2022-06-23T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.3
- calibrated_materiality_score: 0.3
- confidence: high
- sec_items: 5.03, 5.07, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1539029/000095017022012039/0000950170-22-012039-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1539029/000095017022012039/clsd-20220622.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-22-012039
- JSON: https://secwatch.observer/filing/0000950170-22-012039.json
- Plain text: https://secwatch.observer/filing/0000950170-22-012039.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.